BridgeMD
DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority randomized controlled trial, embedded in the TREAT NL registry.
EU CTIS ID: 2023-504171-24-00
What this study is testing
To evaluate and compare the efficacy of dupilumab 300 mg every 2 weeks, every 3 weeks and every 4 weeks, 16 weeks after randomization.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The subject is an adult.
- The subject has a diagnosis of atopic eczema.
- The subject receives dupilumab 300 mg every 2 weeks for the treatment of atopic eczema.
- The subject has controlled disease according to the Treat-to-Target criteria.
- The subject has voluntarily signed and dated an informed consent prior to any study related procedure or has a legal representative to do so and is willing to comply with the requirements of this study protocol.
You likely can't join if
- The subject uses or initiates other systemic immunomodulating therapy for atopic eczema or another diagnosis.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.